Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting

<p>Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia FIGURE 1 Primary Endpoint (n=35): Average number of nausea pills. Overall significance (Type 3 F test): p=0.0007 ROCKAWAY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/data-highlighting-non-invasive-vagus-nerve-stimulation-nvns-for-treatment-of-symptoms-of-gastroparesis-presented-at-2023-american-college-of-gastroenterology-annual-meeting/">Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>